Recent Analysts’ Ratings Updates for Humana (HUM)
by Amy Steele · The Cerbat GemA number of research firms have changed their ratings and price targets for Humana (NYSE: HUM):
- 1/7/2026 – Humana was downgraded by analysts at Wells Fargo & Company from an “overweight” rating to a “cautious” rating.
- 1/7/2026 – Humana had its “equal weight” rating reaffirmed by analysts at Wells Fargo & Company. They now have a $290.00 price target on the stock.
- 1/6/2026 – Humana had its “outperform” rating reaffirmed by analysts at Sanford C. Bernstein. They now have a $344.00 price target on the stock.
- 1/5/2026 – Humana had its “underperformer” rating reaffirmed by analysts at Barclays PLC.
- 1/5/2026 – Humana had its price target raised by analysts at Barclays PLC from $234.00 to $245.00. They now have an “equal weight” rating on the stock.
- 1/1/2026 – Humana was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating.
- 12/18/2025 – Humana had its “underperform” rating reaffirmed by analysts at Morgan Stanley.
- 12/17/2025 – Humana had its price target lowered by analysts at Morgan Stanley from $277.00 to $262.00. They now have an “equal weight” rating on the stock.
- 12/12/2025 – Humana had its “sector weight” rating reaffirmed by analysts at KeyCorp.
- 12/11/2025 – Humana had its price target lowered by analysts at Robert W. Baird from $280.00 to $264.00. They now have a “neutral” rating on the stock.
- 12/5/2025 – Humana was upgraded by analysts at Jefferies Financial Group Inc. from a “hold” rating to a “buy” rating. They now have a $313.00 price target on the stock, up previously from $253.00.
- 11/25/2025 – Humana had its price target lowered by analysts at Barclays PLC from $245.00 to $234.00. They now have an “equal weight” rating on the stock.
- 11/24/2025 – Humana had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $235.00 to $215.00. They now have a “sell” rating on the stock.
- 11/20/2025 – Humana had its price target lowered by analysts at Wolfe Research from $313.00 to $300.00. They now have an “outperform” rating on the stock.
- 11/10/2025 – Humana had its price target lowered by analysts at Truist Financial Corporation from $300.00 to $285.00. They now have a “hold” rating on the stock.
Humana Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Friday, December 26th will be issued a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, December 26th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.3%. Humana’s dividend payout ratio (DPR) is currently 33.18%.
Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.
In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.